RegulationFast Track (United States), Emergency Use Authorization (United States), Emergency Use Authorization (India), Emergency Use Authorization (Thailand), Conditional marketing approval (European Union), Emergency Use Authorization (Taiwan Province)

Structure/Sequence

Sequence Code 708729224

Clinical Trials associated with SARS-CoV-2 Spike Protein Vaccine(Recombinant)(Novavax, Inc.)

NCT06291857

/ Active, not recruitingPhase 3

A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a COVID-19 Influenza Combination Nanoparticle Vaccine and a Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants ? 65 Years of Age.

This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine. The researchers conducting the study won't know which vaccine each participant receives, ensuring their observations are unbiased. This study compares the new combination vaccine to an already available flu vaccine to see how well it works. It's a large-scale, final-stage study designed to thoroughly check how well the vaccines trigger an immune response (immunogenicity) and how safe they are.

Start Date09 Dec 2024

Sponsor / Collaborator

Novavax, Inc.

NCT06065176

/ CompletedPhase 4IIT

Booster Epidemiological Evaluation of Health, Illness and Vaccine Efficacy Study: Randomized Trial to Compare the Clinical Efficacy of Novavax vs. mRNA COVID-19 2023-2024 Updated Vaccines Among Adults 18-49 and 50+ Years in the United States

The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024 updated vaccine provides better protection from COVID-19 than not getting a vaccine.
If the participant chooses to get a 2023-2024 updated COVID-19 vaccine as part of this study, they will have a 50/50 chance of receiving either the Novavax or Pfizer mRNA vaccine.
If the participant decides not to get a 2023-2024 updated COVID-19 vaccine, the participant can still participate in other study activities.
STUDY ACTIVITIES:
* An online enrollment survey
* An in-person enrollment visit
* Weekly online surveys for 20 weeks
* Weekly COVID-19 tests for 20 weeks
* Additional online surveys if you have COVID-19 symptoms or tested positive for COVID-19.
* Additional COVID-19 tests if you have COVID-19 symptoms or tested positive.
* Online survey questions in the middle and at the end of the study

Start Date22 Nov 2023

Sponsor / Collaborator

University of Utah

[+2]

NCT05925127

/ CompletedPhase 2/3

A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults ≥ 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines

This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 [prototype Wuhan vaccine with Matrix-M adjuvant] or NVX-CoV2601 [Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant]).

Start Date16 Oct 2023

Sponsor / Collaborator

Novavax, Inc.

100 Clinical Results associated with SARS-CoV-2 Spike Protein Vaccine(Recombinant)(Novavax, Inc.)

100 Translational Medicine associated with SARS-CoV-2 Spike Protein Vaccine(Recombinant)(Novavax, Inc.)

100 Patents (Medical) associated with SARS-CoV-2 Spike Protein Vaccine(Recombinant)(Novavax, Inc.)

157

Literatures (Medical) associated with SARS-CoV-2 Spike Protein Vaccine(Recombinant)(Novavax, Inc.)

01 Nov 2025·PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents

Article

Author: Gschwend, Manuela H. ; Fix, Jonathan ; Gwak, Eunseon ; Vadivale, Muruga ; Choe, Seung-Ah ; Bolormaa, Erdenetuya ; Rousculp, Matthew D. ; Kim, Kyuwon ; Choe, Young June

Background and aims::

Adolescents can have severe/chronic outcomes from COVID-19. Real-world data on relative vaccine effectiveness between mRNA- and protein-based vaccines are limited, and more data are needed on disease outcomes in this age group.

Methods::

The K-COV-N database, COVID-19 vaccine registry and health insurance claims were retrospectively reviewed to identify adolescents (12- to 18-year-olds) in South Korea who received a homologous primary series of NVX-CoV2373 or BNT162b2 and a heterologous or homologous third vaccine dose. Vaccine recipients were propensity score matched to reduce confounding baseline factors. Adjusted hazard ratios (aHRs) for any medically attended COVID-19 postvaccination (starting 14 days after primary series and 7 days after a third dose) were calculated to assess relative vaccine effectiveness every 30 days through a 180-day risk window.

Results::

From February to December 2022, 3174 and 6253 doses of NVX-CoV2373 and BNT162b2, respectively, were administered to South Korean adolescents. Individuals who received NVX-CoV2373 tended to be older, have a disability, and/or have a prior SARS-CoV-2 infection. Propensity score matching resulted in 107 individuals in each primary series group and 701 and 1417 individuals in the NVX-CoV2373 and BNT162b2 third-dose groups, respectively. The aHR (95% CI) for NVX-CoV2373 compared with BNT162b2 for medically attended COVID-19 in the 180-day risk window was 0.57 (0.31–1.05) for the primary series and 0.68 (0.54–0.84) for the third dose.

Conclusions::

These results suggest that NVX-CoV2373 may provide more robust protection against medically attended COVID-19 as a third dose, compared with BNT162b2. While the aHR for the primary series also indicated lower risk with NVX-CoV2373, this difference was not statistically significant.

01 Sep 2025·JOURNAL OF INFECTION

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

Article

Author: Cathie, Katrina ; Babbage, Gavin ; Belhadef, Hanane Trari ; Hicks, Alexander ; Faust, Saul N ; Stokes, Matthew ; Thomson, Emma C ; Enever, Yvanne ; Pacurar, Mihaela ; Charlton, Sue ; Osanlou, Rostam ; Mujadidi, Yama F ; Saralaya, Dinesh ; McGregor, Alastair C ; Galiza, Eva ; van der Klaauw, Agatha A ; Bibi, Sagida ; Cornelius, Victoria ; Todd, Shirley ; Janani, Leila ; Aley, Parvinder K ; Heath, Paul T ; Andrews, Nick ; Saich, Stephen ; Lambe, Teresa ; Jones, Christine E ; Goodman, Anna L ; Sheridan, Ray ; Harris, Mae ; Palfreeman, Adrian ; Ramsay, Mary ; Moore, Patrick ; Wright, Annie ; Regan, Karen ; Mansfield, Rebecca ; Osanlou, Orod ; Nguyen-Van-Tam, Jonathan S ; Sharma, Sunil ; Baxter, David ; Munro, Alasdair P S ; Liu, Xinxue ; Chatterjee, Krishna ; Read, Robert C ; Bawa, Tanveer ; Green, Christopher A ; Wright, Daniel ; Hallis, Bassam ; Cosgrove, Catherine ; Bula, Marcin ; Minassian, Angela M ; Kanji, Nasir ; Holliday, Kyra ; Llewelyn, Martin J ; Libri, Vincenzo ; Twelves, Chris

BACKGROUND:

Heterologous schedules of booster vaccines for COVID-19 following initial doses of mRNA or adenoviral vector vaccines have been shown to be safe and immunogenic. There are few data on booster doses following initial doses of protein nanoparticle vaccines.

METHODS:

Participants of the phase 3 clinical trial of the COVID-19 vaccine NVX-CoV2373 (EudraCT 2020-004123-16) enroled between September 28 and November 28, 2020, who received 2 doses of NVX-CoV2373 administered 21 days apart were invited to receive a third dose booster vaccine of BNT162b2 (wild type mRNA vaccine) as a sub-study of the COV-BOOST clinical trial, and were followed up for assessment of safety, reactogenicity and immunogenicity to day 242 post-booster.

RESULTS:

The BNT162b2 booster following two doses of NVX-COV2373 was well-tolerated. Most adverse events were mild to moderate, with no serious vaccine-related adverse events reported. Immunogenicity analysis showed a significant increase in spike IgG titres and T-cell responses post-third dose booster. Specifically, IgG levels peaked at day 14 with a geometric mean concentration (GMC) of 216,255 ELISA laboratory units (ELU)/mL (95% CI 191,083-244,743). The geometric mean fold increase from baseline to day 28 post-boost was 168.6 (95% CI 117.5-241.8). Spike IgG titres were sustained above baseline levels at day 242 with a GMC of 58,686 ELU/mL (95% CI 48,954-74,652), with significant decay between days 28 and 84 (geometric mean ratio 0.58, 95% CI 0.53-0.63). T-cell responses also demonstrated enhancement post-booster, with a geometric mean fold increase of 5.1 (95% CI 2.9-9.0) at day 14 in fresh samples and 3.0 (95% CI 1.8-4.9) in frozen samples as measured by ELISpot. In an exploratory analysis, participants who received BNT162b2 after two doses of NVX-COV2373 exhibited higher anti-spike IgG at Day 28 than those who received homologous three doses of BNT162b2, with a GMR of 5.02 (95% CI: 3.17-7.94). This trend remained consistent across all time points, indicating a similar decay rate between the two schedules.

CONCLUSIONS:

A BNT162b2 third dose booster dose in individuals primed with two doses of NVX-COV2373 is safe and induces strong and durable immunogenic responses, higher than seen in other comparable studies. These findings support the use and investigation of heterologous booster strategies and early investigation of heterologous vaccine technology schedules should be a priority in the development of vaccines against new pathogens.

01 Aug 2025·VACCINE

COVID-19 vaccine (NVX-CoV2373 and NVX-CoV2540) doses and virus strain match impact sex- and age-specific immunity and protection in mice

Article

Author: Liu, Jennifer A ; Park, Han-Sol ; Guebre-Xabier, Mimi ; Creisher, Patrick S ; Klein, Sabra L ; Lee, John S ; Pekosz, Andrew ; Smith, Gale ; Patel, Nita ; Sachithanandham, Jaiprasath ; Chaulagain, Sabal

Sex and age impact immune responses to diverse vaccines. Using a preclinical mouse model, we investigated immune responses to a COVID-19 spike (S) protein-based vaccine and booster doses in adult (25 weeks) and aged (64 weeks) male and female C57BL/6 mice. Mice were intramuscularly vaccinated with either two doses of NVX-CoV2373 (Ancestral Wuhan-Hu-1) or two doses of NVX-CoV2373 followed by a booster of NVX-CoV2540 (Omicron BA.5) in 3-week intervals. Steroid concentrations, antibody titers, and immune cell frequencies in draining lymph nodes were quantified. Three weeks post-boost, subsets of mice were challenged with SARS-CoV-2 (Mu variant B.1.621) to measure cross-protection against an antigenically distinct strain. After two ancestral vaccine doses, adult females had greater binding antibody titers than either adult males or aged females, that were positively correlated with circulating estradiol concentrations. Adult females also had greater cross-neutralizing antibodies and had lower viral titers in respiratory tissues following live virus challenge than adult males. Aged mice, particularly males, had lower antibody titers and frequencies of B and follicular helper T cells than adult mice that were not cross-protective against B.1.621 challenge. Immunization with the BA.5 booster improved antibody responses and B and T cell frequencies in both adults and aged mice, eliminating sex and age differences in immunity and protection from SARS-CoV-2 challenge. These data highlight that there are limits to cross-protective immunity, particularly among males and aged individuals, that can be improved through booster doses that more closely match the challenge SARS-CoV-2 virus.

594

News (Medical) associated with SARS-CoV-2 Spike Protein Vaccine(Recombinant)(Novavax, Inc.)

24 Oct 2025

·www.biospace.com

Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots

Map with different syringes. Covid 19 and pandemic vaccination concept. Vector illustration iStock, Overearth Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing pressures in Europe. Sales of Sanofi’s legacy vaccines business declined nearly 8% in the third quarter to €3.36 billion ($3.9 billion) amid falling flu and COVID-19 vaccination rates in the U.S. For those two vaccines, sales declined nearly 17% for €1.53 billion ($1.78 billion) for the period, according to a third quarter earnings report released Friday morning. Sanofi said the result was in line with full year expectations. “As expected, our flu vaccines business declined because of increased price competition and lower vaccination rate,” CEO Paul Hudson said in a statement. The vaccines also faced pricing pressure elsewhere in the world, particularly in Germany, the company said. Other vaccines in Sanofi’s stable include Beyfortus for protection against respiratory syncytial virus (RSV) lower respiratory tract disease. The shot notched €739 million ($858 million) in sales, a nearly 20% increase. This was driven by roll outs around the world, as it is now available in 40 countries. In the second quarter, Sanofi’s vaccine business grew 10% thanks to Beyfortus. Hudson during that earnings call in July also noted a bump from late 2024-2025 flu season in the Northern Hemisphere. Due to the seasonal nature of flu and RSV, Sanofi typically expects the second half of the year to be the most profitable for the vaccine business, he said. Sanofi was already expecting “competitive forces” to pressure vaccine sales with an expected decrease in the “mid-teens percentage,” CFO François-Xavier Roger said on the second quarter call. Still, Sanofi expected to gain market share. Roger expected sales to split about 75% in the third quarter and 25% in the fourth. Sanofi executives were asked at that time if Health and Human Services Secretary Robert F. Kennedy Jr.’s campaign to overhaul vaccine policy in the U.S. was having any effect. “I don’t have any specific comment on the new administration view on flu,” Thomas Triomphe, executive vice president of Vaccines, said at the time. While Kennedy has taken steps to restrict access to COVID-19 vaccines, he has not changed flu recommendations in the U.S. Meanwhile, data from the Centers for Disease Control and Prevention show that vaccine rates for common childhood shots have declined . The CDC has not yet begun reporting weekly flu vaccine data as the 2025/26 season gets underway. Sanofi’s COVID-19 vaccine Nuvaxovid comes from Novavax. The two companies partnered in May 2024 with Sanofi taking over commercialization of the shot. Novavax received $500 million upfront plus $700 million in potential milestones. The partners have been working on a combo COVID/flu vaccine as well. In its Q3 earnings report, Sanofi said the company is in talks with regulators after the SP0287 program delivered preliminary positive results. Also in the earnings report, Sanofi announced the discontinuation of the SP0125 RSV vaccine for toddlers. A futility analysis determined that the vaccine had insufficient efficacy in the Phase III PEARL trial

VaccinePhase 3Clinical ResultFinancial Statement

24 Oct 2025

·www.biopharmadive.com

Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales

Sanofi on Friday reported a sharp decline in quarterly vaccine sales, a development the French company partially tied to lower immunization rates in the U.S.In its latest earnings report, Sanofi said that its overall vaccine sales fell by 7.8% to 3.4 billion, or $3.9 billion, between July and September. The pullback was largely driven by a slowdown in influenza shots, which, combined with the revenue Sanofi derives from Novavaxs COVID-19 vaccine Nuvaxovid, decreased by 16.8%, to 1.5 billion. Sanofis COVID-19 and influenza vaccine sales are down a total of 14% this year, the company said.In prepared remarks and on an earnings call with analysts, Sanofi executives claimed the lower numbers were expected. CEO Paul Hudson cited price competition in Germany and a slowdown in the U.S.It's early. We're still in October. But I think it's fair that with the first few weeks that we observed a little bit of vaccination rate on the soft side when it comes to flu vaccination, particularly in the U.S., Thomas Triomphe, Sanofis head of vaccines R&D, told analysts.Vaccines have faced heightened commercial pressure in the U.S. since the confirmation of Health and Human Services Secretary Robert F. Kennedy, Jr. Kennedy overhauled a key committee guiding U.S. vaccine policy, replacing themwith a handpicked groupmore aligned with his skeptical views on immunizations.The Food and Drug Administration has also set in place a stricter framework for COVID-19 shots, leading to narrower clearances than in years past.Over that time, vaccination rates for routine childhood immunizations have declined, even as a measles outbreak has taken hold. Rates of flu shots have also been in a prolonged downswing in the U.S., according to a report earlier this year from the nonprofit group PLOS Global Health.Sanofi, one of the worlds preeminent vaccine makers, continues to invest in the space, however. The company, for instance, has multiple combination shots for influenza and other viruses in development.Sanofi has a proud legacy of flu vaccines, and we remain committed on bringing innovation to strengthen our leadership in flu and to provide better protection for patients, Hudson said Friday.Despite the slowdown in vaccine sales, Sanofis overall revenue rose by 2.3%, boosted in part by revenue for its blockbuster anti-inflammatory drug Dupixent. Sales of Dupixent surged by 26.2% to 4.2 billion, a quarterly record that beat consensus estimates, wrote Leerink Partners analyst David Risinger.Sanofis Beyfortus, a preventive drug for respiratory syncytial virus in infants, also bested Wall Street projections. Sales jumped 14.6% to 739 million, or about $860 million, between April and June.Newer drug launches which include the hemophilia medication Altuviiio and Ayvakit, a rare disease therapy acquired in Sanofis buyout of Blueprint Medicines climbed 57.1%, reaching 1 billion for the quarter. '

VaccineAcquisition

22 Oct 2025

·www.fiercepharma.com

Consolidating Novavax transfers Maryland HQ lease to AstraZeneca in $60M deal

Novavax is handing over its long-term Gaithersburg lease to AstraZeneca with a start date of January 2026. Novavax is slimming down again by striking a deal to transfer the lease to its Maryland corporate headquarters to AstraZeneca in exchange for nearly $60 million.The Gaithersburg, Maryland-based vaccine maker plans to let go of the facility in an effort to better focus on R&D and partnerships as part of its corporate strategy, the company said in an Oct. 22 press release. In essence, the company aims to maintain "necessary capabilities" in only the “leanest and most cost-effective manner." Novavax will remain headquartered in Gaithersburg, moving to a new address that’s just down the road, an Oct. 17 SEC filing shows.According to the filing, AstraZeneca will officially take over Novavax’s multi-year lease on Jan. 5, 2026, for $59.8 million. The lease expires in December of 2036.The deal includes the lease reassignment and the sale of certain related assets, according to the filing.Novavax expects to record a non-cash impairment charge of between $96 million and $98 million during this year’s third quarter, but it estimates cost savings of $230 million over the 11-year period related to the lease and operating costs. "This consolidation of our facilities in Maryland results in upfront cash and significant cash savings related to our lease liabilities and future operating costs while enabling Novavax to better focus on pipeline and technology investments,” CEO John C. Jacobs explained in the release. With the deal, AZ is slated to add about 171,000 square feet of space in Gaithersburg. The British drugmaker already has a significant footprint in the city, operating a R&D campus that houses more than 3,000 staffers. In addition, AZ recently expanded its force in Maryland with the addition of a $300 million cell therapy site in Frederick.As for Novavax, the deal is the latest in its consolidation efforts. Last year saw a $200 million sale of a 150,000-square-foot recombinant protein facility in Bohumil, Czech Republic, to Novo Nordisk, a deal that included support buildings and a transfer of the plant's workforce.Besides its consolidation efforts, Novavax's product-related revenue stems from its non-mRNA COVID-19 vaccine Nuvaxovid and related partnerships with Sanofi and Takeda.Sanofi stepped in to help with Novavax’s COVID vaccine efforts last year, taking a 4.9% equity position in the vaccine maker and striking a $1.2 billion collaboration. The vaccine’s U.S. approval in May triggered a $175 million payment from Sanofi, with another payout of $25 million recorded earlier this month after Novavax transferred over Nuvaxovid’s European marketing authorization. Takeda, meanwhile, has signed on to market the drug in Japan.Novavax’s partnerships are key to keeping the company afloat as sales continue to struggle. After generating $984 million in 2023, the drugmaker logged $682 million in full-year 2024 sales and most recently reported $239 million during the second quarter of 2025, a 42% dip from the same period last year.

VaccineDrug ApprovalClinical StudymRNA

100 Deals associated with SARS-CoV-2 Spike Protein Vaccine(Recombinant)(Novavax, Inc.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15810

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
COVID-19	European Union	Sanofi Winthrop Industrie SA	20 Dec 2021
COVID-19	Iceland	Sanofi Winthrop Industrie SA	20 Dec 2021
COVID-19	Liechtenstein	Sanofi Winthrop Industrie SA	20 Dec 2021
COVID-19	Norway	Sanofi Winthrop Industrie SA	20 Dec 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 3	Australia	Novavax, Inc.	09 Dec 2024
Influenza, Human	Phase 3	New Zealand	Novavax, Inc.	09 Dec 2024
SARS-CoV-2 sepsis	Phase 3	United States	Novavax, Inc.	16 Oct 2023
Severe Acute Respiratory Syndrome	Phase 3	United Kingdom	Novavax, Inc.	28 Sep 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05875701 (CTgov)	Phase 3	COVID-19	147	NVX-CoV2373	lgxvppavzx(scgbeyuyom) = jvgtjatlae utmvjxfgcy (wruwgzuqww, soaxpziuag - ebtwdlvacg) View more	-	26 Jun 2025
NCT05299359 (TAK-019-3001, Pubmed \| Vaccine)	Phase 3	COVID-19	129	NVX-CoV2373	idukbuwvey(cugcrfkawz) = jxfxqotmud ajhtlkmipw (krfojbhofd ) View more	Positive	01 Jan 2024
NCT05299359 (TAK-019-3001, CTgov)	Phase 3	COVID-19	150	TAK-019 (Main Part: Day 15 of This Study: TAK-019)	figmpdsrds(skgvgpuqbq) = sqqnwlixni dispqgsbco (znsorxkcmy, fsdndwtsrr - zprivjqurx)	-	28 Jul 2023
				TAK-019-1501 (Day 36 for TAK-019-1501 Study)	figmpdsrds(skgvgpuqbq) = ghgslvqybb dispqgsbco (znsorxkcmy, nhmwilwuph - bhuqgoirxe)
NCT04712110 (CTgov)	Phase 1/2	COVID-19	200	Placebo (Placebo)	mrivsnxzpu = nqdgbatquz tvfwvdufsq (hnhgwmbykn, cvnggquftm - xdkghbzyrj) View more	-	06 Jun 2023
				TAK-019 (TAK-019)	qwsstkzbcb(aszdxzhlto) = jpwbfkscqx lzjyeeimfl (ftadlaavky, aziospotdl - baeldozoqt) View more
NCT04611802 (PREVENT-19, Pubmed \| Vaccine)	Phase 3	COVID-19 \| Severe Acute Respiratory Syndrome	-	NVX-CoV2373 vaccine	iujeezmsus(wfpzyjlnql) = rbzetljlah dbgdjawwuh (icddjmsnvd )	Positive	01 May 2023
				Placebo	pkudlobkqv(jvtbyvrwzk) = yrhkyxrleo fuujettjtu (fkadecyofw, 83.1 - 100)
NCT04611802 (PREVENT-19, Pubmed)	Phase 3	COVID-19	2,232	NVX-CoV2373	chggjlkoex(gumeqaicpc) = acgoyhxbgx pelfcqtusb (vhvscypkfc, 1.31 - 6.46) View more	Positive	03 Apr 2023
				Placebo	chggjlkoex(gumeqaicpc) = mngkemxidj pelfcqtusb (vhvscypkfc, 8.42 - 23.93)
Biospace Manual	Phase 1/2	COVID-19 \| Influenza, Human	642	NVX-CoV2373	cgqrortydx(etvoivvnzy) = Serious adverse events were rare, and none were assessed as being related to the vaccine. kecgbpeeab (ilyphzkskn )	Positive	13 Oct 2022
NCT04611802 (PREVENT-19, Pubmed) Manual	Phase 3	COVID-19	2,247	NVX-CoV2373	bucnzsinju(dsontftxzi) = largely mild-to-moderate, transient, and more frequent in NVX-CoV2373 recipients and after the second dose. vfbntvtuyp (xguhwdelsa ) View more	Positive	21 Sep 2022
				Placebo
NCT04712110 (Pubmed \| Vaccine)	Phase 1/2	-	200	NVX-CoV2373 (TAK-019) vaccineNVX-CoV2373 (TAK-019) vaccine (NVX-CoV2373)	srjpumqmcn(aoriqfffze) = Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. ddcevasqtq (djlibzmlnt )	Positive	29 Apr 2022
				NVX-CoV2373 (TAK-019) vaccine (Placebo)
NCT04583995 (Pubmed) Manual	Phase 3	COVID-19	15,187	NVX-CoV2373	fbfcvjrudi(juflkzqoqp) = yvdzzopxmu dtwbybxqra (bmuljipmut ) View more	Positive	23 Sep 2021
				Placebo	fbfcvjrudi(juflkzqoqp) = frtalqdyxq dtwbybxqra (bmuljipmut ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis